Allergic Rhinitis – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Allergic Rhinitis – Pipeline Review, H1 2017’, provides an overview of the Allergic Rhinitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis

The report reviews pipeline therapeutics for Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Allergic Rhinitis therapeutics and enlists all their major and minor projects

The report assesses Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Allergic Rhinitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Accolade Pharmaceuticals LLC

AFFiRiS AG

ALK-Abello A/S

AlleCures Inc

Allergy Therapeutics Plc

ASIT Biotech SA

Axikin Pharmaceuticals Inc

Chong Kun Dang Pharmaceutical Corp

Chrysalis BioTherapeutics Inc

Fountain Biopharma Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

HAL Allergy BV

Hisamitsu Pharmaceutical Co Inc

Intrommune Therapeutics

J Uriach Y Compania SA

Laboratorios LETI SL

Paradigm Biopharmaceuticals Ltd

Pfizer Inc

Sanofi

Stallergenes Greer plc

Sun Pharma Advanced Research Company Ltd

Taiho Pharmaceutical Co Ltd

Therabron Therapeutics Inc

VentiRx Pharmaceuticals Inc

Xencor Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Allergic Rhinitis - Overview 7

Allergic Rhinitis - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 19

Allergic Rhinitis - Therapeutics Assessment 20

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Allergic Rhinitis - Companies Involved in Therapeutics Development 28

Accolade Pharmaceuticals LLC 28

AFFiRiS AG 28

ALK-Abello A/S 29

AlleCures Inc 30

Allergy Therapeutics Plc 30

ASIT Biotech SA 31

Axikin Pharmaceuticals Inc 31

Chong Kun Dang Pharmaceutical Corp 32

Chrysalis BioTherapeutics Inc 32

Fountain Biopharma Inc 33

GlaxoSmithKline Plc 33

Glenmark Pharmaceuticals Ltd 34

HAL Allergy BV 34

Hisamitsu Pharmaceutical Co Inc 35

Intrommune Therapeutics 35

J Uriach Y Compania SA 36

Laboratorios LETI SL 36

Paradigm Biopharmaceuticals Ltd 37

Pfizer Inc 37

Sanofi 38

Stallergenes Greer plc 38

Sun Pharma Advanced Research Company Ltd 39

Taiho Pharmaceutical Co Ltd 39

Therabron Therapeutics Inc 40

VentiRx Pharmaceuticals Inc 40

Xencor Inc 41

Allergic Rhinitis - Drug Profiles 42

(fexofenadine hydrochloride + phenylephrine hydrochloride) - Drug Profile 42

(mometasone furoate + olopatadine hydrochloride) - Drug Profile 43

854-A - Drug Profile 44

Allergen for Allergic Conjunctivitis and Allergic Rhinitis - Drug Profile 45

Allergen for Allergic Rhinitis - Drug Profile 46

Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile 47

Allergen for Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 48

Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile 49

Allergen for Asthma and Perennial Allergic Rhinitis - Drug Profile 50

Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 51

Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 53

Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 54

Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 55

Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile 56

arabinogalactan - Drug Profile 57

B-244 - Drug Profile 58

bepotastine besilate SR - Drug Profile 60

budesonide - Drug Profile 61

CBP-174 - Drug Profile 62

CG-201 - Drug Profile 63

CPC-888 - Drug Profile 64

emedastine difumarate - Drug Profile 65

FB-825 - Drug Profile 66

gp-ASIT - Drug Profile 67

GSK-2245035 - Drug Profile 70

KR-62980 - Drug Profile 72

Lactococcus lactis G121 - Drug Profile 74

levocabastine hydrochloride + mometasone furoate - Drug Profile 75

mometasone furoate - Drug Profile 76

Monoclonal Antibody for Seasonal Allergic Rhinitis - Drug Profile 77

nasapaque - Drug Profile 78

pentosan polysulfate sodium - Drug Profile 79

PF-06444753 - Drug Profile 82

Pollinex Quattro Tree - Drug Profile 84

rag-ASIT - Drug Profile 86

rupatadine - Drug Profile 87

Small Molecule for Allergic Rhinitis - Drug Profile 88

Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases - Drug Profile 89

Small Molecules for Respiratory Disorders - Drug Profile 90

Small Molecules for Seasonal Allergic Rhinitis - Drug Profile 91

Small Molecules to Antagonize H1 and H3 Receptor for Allergic Rhinitis - Drug Profile 92

Small Molecules to Inhibit PGD2 Synthase for Asthma and Allergic Rhinitis - Drug Profile 93

standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile 94

standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile 97

STG-120 - Drug Profile 102

SUN-0597 - Drug Profile 103

SYM-001 - Drug Profile 105

TAS-205 - Drug Profile 106

TO-206 - Drug Profile 107

Vaccine for Asthma and Allergic Rhinitis - Drug Profile 108

Vaccine to Target IgE for Allergic Rhinitis and Asthma - Drug Profile 109

VTX-1463 - Drug Profile 110

XmAb-7195 - Drug Profile 111

Zafi-3 - Drug Profile 113

zafirlukast - Drug Profile 114

Allergic Rhinitis - Dormant Projects 115

Allergic Rhinitis - Discontinued Products 121

Allergic Rhinitis - Product Development Milestones 123

Featured News & Press Releases 123

Appendix 132

Methodology 132

Coverage 132

Secondary Research 132

Primary Research 132

Expert Panel Validation 132

Contact Us 132

Disclaimer 133

List of Tables

List of Tables

Number of Products under Development for Allergic Rhinitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Allergic Rhinitis – Pipeline by Accolade Pharmaceuticals LLC, H1 2017

Allergic Rhinitis – Pipeline by AFFiRiS AG, H1 2017

Allergic Rhinitis – Pipeline by ALK-Abello A/S, H1 2017

Allergic Rhinitis – Pipeline by AlleCures Inc, H1 2017

Allergic Rhinitis – Pipeline by Allergy Therapeutics Plc, H1 2017

Allergic Rhinitis – Pipeline by ASIT Biotech SA, H1 2017

Allergic Rhinitis – Pipeline by Axikin Pharmaceuticals Inc, H1 2017

Allergic Rhinitis – Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017

Allergic Rhinitis – Pipeline by Chrysalis BioTherapeutics Inc, H1 2017

Allergic Rhinitis – Pipeline by Fountain Biopharma Inc, H1 2017

Allergic Rhinitis – Pipeline by GlaxoSmithKline Plc, H1 2017

Allergic Rhinitis – Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017

Allergic Rhinitis – Pipeline by HAL Allergy BV, H1 2017

Allergic Rhinitis – Pipeline by Hisamitsu Pharmaceutical Co Inc, H1 2017

Allergic Rhinitis – Pipeline by Intrommune Therapeutics, H1 2017

Allergic Rhinitis – Pipeline by J Uriach Y Compania SA, H1 2017

Allergic Rhinitis – Pipeline by Laboratorios LETI SL, H1 2017

Allergic Rhinitis – Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2017

Allergic Rhinitis – Pipeline by Pfizer Inc, H1 2017

Allergic Rhinitis – Pipeline by Sanofi, H1 2017

Allergic Rhinitis – Pipeline by Stallergenes Greer plc, H1 2017

Allergic Rhinitis – Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Allergic Rhinitis – Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017

Allergic Rhinitis – Pipeline by Therabron Therapeutics Inc, H1 2017

Allergic Rhinitis – Pipeline by VentiRx Pharmaceuticals Inc, H1 2017

Allergic Rhinitis – Pipeline by Xencor Inc, H1 2017

Allergic Rhinitis – Dormant Projects, H1 2017

Allergic Rhinitis – Dormant Projects, H1 2017 (Contd..1), H1 2017

Allergic Rhinitis – Dormant Projects, H1 2017 (Contd..2), H1 2017

Allergic Rhinitis – Dormant Projects, H1 2017 (Contd..3), H1 2017

Allergic Rhinitis – Dormant Projects, H1 2017 (Contd..4), H1 2017

Allergic Rhinitis – Dormant Projects, H1 2017 (Contd..5), H1 2017

Allergic Rhinitis – Discontinued Products, H1 2017

Allergic Rhinitis – Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

List of Figures

Number of Products under Development for Allergic Rhinitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports